TY - JOUR
T1 - Serologic analysis of human tumor antigens. I. antisarcoma antibodies in the sera of patients with osteogenic sarcomas
AU - Thorpe, William P.
AU - Rosenberg, Steven A.
N1 - Funding Information:
I Received May 30, 1978; accepted October 31, 1978. 2 Surgery Branch, National Cancer Institute, National Institutes of Health, Public Health Service, Department of Health, Education, and Welfare, Bethesda, Md. 20014. 3 Address reprint requests to Dr. Rosenberg. 4 We thank Ms. Neal Hyatt for her excellent help in establishing and maintaining the tissue culture lines used in this study.
PY - 1979/5
Y1 - 1979/5
N2 - Using absorptions with human fetal tissue, we attempted to detect reactivity in the sera of patients with osteogenic sarcomas against antigens on autologous osteogenic sarcoma cells that are not on autologous normal cells. Quantitative absorptions revealed that 10‘ viable human fetal cells were capable of absorbing all reactivity from sarcoma-bearing patients’ sera against autologous skin cells in tissue culture. In 2 patients with osteogenic sarcomas, exhaustive quantitative absorption with human fetal tissue removed all reactivity against autologous normal skin cells but left activity against autologous osteogenic sarcoma cells in tissue culture. The sarcoma-reactive serum from 0 patient (J. B.) was tested against the normal and sarcoma cells from 4 additional patients. This serum reacted with osteogenic sarcoma cells from only 1 other patient (L. S.) and with none of the normal cells. After fetal absorption, sera from all 5 patients, however, reacted with sarcoma cells from patients J. B. and L. S. but not with normal cells from J. B. and L. S. Sera from patients with osteogenic sarcomas appeared to contain antibodies against both fetal-and tumor-related antigens expressed on osteogenic sarcoma cells in tissue culture. Reactivity against the tumor cells but not against the normal cells was apparent only following extensive absorption of these sera with human fetal tissue.-.
AB - Using absorptions with human fetal tissue, we attempted to detect reactivity in the sera of patients with osteogenic sarcomas against antigens on autologous osteogenic sarcoma cells that are not on autologous normal cells. Quantitative absorptions revealed that 10‘ viable human fetal cells were capable of absorbing all reactivity from sarcoma-bearing patients’ sera against autologous skin cells in tissue culture. In 2 patients with osteogenic sarcomas, exhaustive quantitative absorption with human fetal tissue removed all reactivity against autologous normal skin cells but left activity against autologous osteogenic sarcoma cells in tissue culture. The sarcoma-reactive serum from 0 patient (J. B.) was tested against the normal and sarcoma cells from 4 additional patients. This serum reacted with osteogenic sarcoma cells from only 1 other patient (L. S.) and with none of the normal cells. After fetal absorption, sera from all 5 patients, however, reacted with sarcoma cells from patients J. B. and L. S. but not with normal cells from J. B. and L. S. Sera from patients with osteogenic sarcomas appeared to contain antibodies against both fetal-and tumor-related antigens expressed on osteogenic sarcoma cells in tissue culture. Reactivity against the tumor cells but not against the normal cells was apparent only following extensive absorption of these sera with human fetal tissue.-.
UR - http://www.scopus.com/inward/record.url?scp=0018365201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018365201&partnerID=8YFLogxK
U2 - 10.1093/jnci/62.5.1143
DO - 10.1093/jnci/62.5.1143
M3 - Article
C2 - 286090
AN - SCOPUS:0018365201
SN - 0027-8874
VL - 62
SP - 1143
EP - 1151
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 5
ER -